Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In a rat model of benign prostatic hyperplasia, this study found that purple corn extract may improve symptoms by inhibiting prostate enlargement, reducing androgen receptor signaling, and exerting anti-inflammatory effects.

In this study, androgenetic alopecia patients with thin hair were found to have a higher likelihood of experiencing prostatic enlargement and related urinary symptoms compared to those with thicker hair.

This review discusses the impact of COVID-19 on lower urinary tract symptoms and benign prostatic enlargement, noting altered patient care and management, but provides no new clinical results.

In this large British study, prostate cancer risk was linked to ethnicity, family history, prostate enlargement, and PSA testing, while excess adiposity, smoking, diabetes, and certain lifestyle factors were associated with a reduced risk.

This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.

This study found that severe obesity is positively associated with more severe lower urinary tract symptoms compared to moderate obesity in patients with prostatic enlargement.

Combining α-blockers and Finasteride is useful for treating small prostate enlargement.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This study found that methanol extract from Sapium rotundifolium Hemsl. reduced prostate enlargement and related protein expressions in testosterone-induced benign prostatic hyperplasia models in both cells and rats.

This study found that testosterone therapy increased bone mineral density in older men with low testosterone, and combining it with finasteride may reduce prostate enlargement associated with testosterone treatment.

In this pilot randomized clinical trial, TRT combined with finasteride increased lean mass, muscle size, and bone mineral density without prostate enlargement in men with spinal cord injury, suggesting potential benefits for body composition and musculoskeletal health.

This study found that androgenic alopecia may serve as an early marker for benign prostatic hyperplasia.

This animal study found that Cinnamomi cortex water extract reduced prostate weight and improved histological changes in a benign prostatic hyperplasia model, suggesting potential as a treatment.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

In this study, the safety of finasteride in rats varied depending on dosing time, while its effectiveness on prostate weight reduction remained consistent.

This review discusses the historical and current use of androgen manipulation for treating benign prostatic hyperplasia and reports no new clinical results.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

In this review, the role of DHT in male-type obesity and metabolic diseases is discussed, with increased levels potentially exacerbating cardiovascular disease risk; the paper reports no new results.

This study found that finasteride improved urodynamic measures of obstruction in men with benign prostatic enlargement and lower urinary tract symptoms, with continued improvement over two years of treatment.

This review discusses the efficacy of the lipidosterolic extract of Serenoa repens for treating lower urinary tract symptoms and reports no new clinical results; the authors propose further examination of the existing literature and guidelines.

This editorial comments on a European registry evaluating the symptomatic effectiveness of pharmacological treatments for benign prostatic enlargement and presents no new research findings.

This study observed that urologists are more likely than primary care physicians to prescribe a variety of alpha blockers and newer medications, indicating a broader awareness of treatment options for benign prostate enlargement.

This study describes a case where finasteride treatment for benign prostatic hypertrophy was associated with gynecomastia in a 62-year-old man, which resolved after the drug was discontinued.

In this study, researchers found that finasteride induces dysregulation of genes related to neuropsychiatric disorders, including the HOMER-3 gene associated with dementia, and propose exploring craniosacral osteopathic therapy's potential to modulate this gene's methylation profile and alleviate related symptoms.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

This study developed a pharmacokinetic/pharmacodynamic model for finasteride, concluding that finasteride's nonlinear pharmacokinetics are likely due to its saturable binding to 5alphaR2.

This study determined the molecular structure of finasteride and its related crystalline forms, highlighting different hydrogen-bond interactions and structural configurations in various crystalline complexes.

This paper describes a new scalable synthesis method for Dutasteride, highlighting its potential for large-scale commercial production.